Literature DB >> 1872494

The pathogenesis of sepsis.

R C Bone1.   

Abstract

Sepsis and its sequelae (sepsis syndrome and septic shock) are increasingly common and are still potentially lethal diagnoses. Many mediators of the pathogenesis of sepsis have recently been described. These include tumor necrosis factor alpha (TNF alpha), interleukins, platelet activating factor, leukotrienes, thromboxane A2, and activators of the complement cascade. Neutrophil and platelet activation may also play a role. Other agents that may participate in the sepsis cascade include adhesion molecules, kinins, thrombin, myocardial depressant substance, beta-endorphin, and heat shock proteins. Endothelium-derived relaxing factor and endothelin-1 are released from the endothelium and seem to exert a regulatory effect, counterbalancing each other. A central mediator of sepsis does not seem to exist, although TNF alpha has been commonly proposed for this role. Animal studies are difficult to extrapolate to the clinical setting because of cross-species differences and variations in experimental design. Rather than being caused by any single pathogenic mechanism, it is more likely that sepsis is related to the state of activation of the target cell, the nearby presence of other mediators, and the ability of the target cell to release other mediators. Also important is the downregulation or negative feedback of these mediators or the generation of natural inflammation inhibitors, such as interleukin-4 and interleukin-8. Endothelial damage in sepsis probably results from persistent and repetitive inflammatory insults. Eventually, these insults produce sufficient damage that downregulation can no longer occur; this leads to a state of metabolic anarchy in which the body can no longer control its own inflammatory response.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1872494     DOI: 10.7326/0003-4819-115-6-457

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  215 in total

1.  Serum amyloid P component bound to gram-negative bacteria prevents lipopolysaccharide-mediated classical pathway complement activation.

Authors:  C J de Haas; E M van Leeuwen; T van Bommel; J Verhoef; K P van Kessel; J A van Strijp
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

2.  Consequences of interaction of a lipophilic endotoxin antagonist with plasma lipoproteins.

Authors:  J R Rose; M A Mullarkey; W J Christ; L D Hawkins; M Lynn; Y Kishi; K M Wasan; K Peteherych; D P Rossignol
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

3.  Dual role of lipopolysaccharide (LPS)-binding protein in neutralization of LPS and enhancement of LPS-induced activation of mononuclear cells.

Authors:  T Gutsmann; M Müller; S F Carroll; R C MacKenzie; A Wiese; U Seydel
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

4.  Endothelium-derived Toll-like receptor-4 is the key molecule in LPS-induced neutrophil sequestration into lungs.

Authors:  Graciela Andonegui; Claudine S Bonder; Francis Green; Sarah C Mullaly; Lori Zbytnuik; Eko Raharjo; Paul Kubes
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

Review 5.  The nitric oxide pathway in the cardiovascular system.

Authors:  S Llorens; J Jordán; E Nava
Journal:  J Physiol Biochem       Date:  2002-09       Impact factor: 4.158

6.  More on pathogenesis and treatment of septic shock.

Authors:  D Fumarola; S Pece
Journal:  Eur J Epidemiol       Date:  1992-09       Impact factor: 8.082

7.  Interaction of pulmonary surfactant protein C with CD14 and lipopolysaccharide.

Authors:  Luis A Augusto; Monique Synguelakis; Jan Johansson; Thierry Pedron; Robert Girard; Richard Chaby
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

8.  Highly purified vitamin B2 presents a promising therapeutic strategy for sepsis and septic shock.

Authors:  Toshio Toyosawa; Mamoru Suzuki; Kohtarou Kodama; Seiichi Araki
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

9.  Impact of nosocomial polymicrobial bloodstream infections on the outcome in critically ill patients.

Authors:  S Sancho; A Artero; R Zaragoza; J J Camarena; R González; J M Nogueira
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-14       Impact factor: 3.267

10.  Leukemia inhibitory factor protects against experimental lethal Escherichia coli septic shock in mice.

Authors:  P M Waring; L J Waring; T Billington; D Metcalf
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.